NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Get Free Report)’s share price rose 0.4% during mid-day trading on Monday . According to data from MarketBeat, NeuroSense Therapeutics has an average rating of “Moderate Buy” and an average price target of $8.50. Get NeuroSense Therapeutics alerts:Check Out Our Latest Stock Analysis on NeuroSense TherapeuticsNeuroSense Therapeutics Stock PerformanceInsider ActivityThe company has a market capitalization of $17.64 million, a P/E ratio of -0.86 and a beta of 1.62. NeuroSense Therapeutics Company Profile(Get Free Report)NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. See AlsoReceive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.